Management of anticoagulation in patients with prostate cancer receiving enzalutamide

Joseph J. Shatzel, Molly M. Daughety, Sven R. Olson, Tomasz (Tom) Beer, Thomas Deloughery

    Research output: Contribution to journalReview article

    4 Scopus citations


    Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.

    Original languageEnglish (US)
    Pages (from-to)720-727
    Number of pages8
    JournalJournal of Oncology Practice
    Issue number11
    StatePublished - Nov 1 2017

    ASJC Scopus subject areas

    • Oncology
    • Oncology(nursing)
    • Health Policy

    Fingerprint Dive into the research topics of 'Management of anticoagulation in patients with prostate cancer receiving enzalutamide'. Together they form a unique fingerprint.

  • Cite this